SD Bioline malaria antigen Pf (HRP-2/pLHD) for assessing efficacy of artemisinin combination therapy against Plasmodium falciparum in pediatric patients in the Democratic Republic of the Congo by Kilauzi, Albert Lukuka et al.




SD Bioline malaria antigen Pf (HRP-2/pLHD) for assessing efficacy of artemisinin 
combination therapy against Plasmodium falciparum in pediatric patients in the 
Democratic Republic of the Congo 
 
Albert Lukuka Kilauzi1, Jose Gaby Tshikuka Mulumba2,&, Mgaywa Gilbert Mjungu Damas Magafu2, Reginald Matchaba-Hove3, Roy 
Tapera3, Naoko Shimizu Magafu4, Jean Jacques Muyembe Tamfum1 
 
1National Biomedical Research Institute (INRB), Democracy Avenue, P. O. Box 1197, Gombe, Kinshasa, the Democratic Republic of the 
Congo, 2Department of Public Health Medicine, Faculty of Medicine, University of Botswana, Private bag 00713, Gaborone, Botswana, 3School of 
Public Health, Faculty of Health Sciences, University of Botswana, Private Bag 0022, Gaborone, Botswana, 4Japan Overseas Christian Medical Co-
operative Services, C/o Roman Catholic Archdiocese of Tabora, Private Bag, Tabora, Tanzania 
 
&Corresponding author: Jose Gaby Tshikuka Mulumba, Department of Public Health Medicine, Faculty of Medicine, University of Botswana, Private 
bag 00713, Gaborone, Botswana 
 
Key words: Malaria, AgPf(HRP-2/pLDH) RDT, artemisinin combination therapy, Democratic Republic of the Congo 
 
Received: 15/02/2015 - Accepted: 15/06/2015 - Published: 25/11/2015 
 
Abstract  
Introduction: The emergence of Plasmodium falciparum resistance to artemisinin combination therapy (ACT) is a worrying development. It calls 
for close surveillance to monitor the efficacy of the drugs. The objectives of this study were to determine the performance of SD Bioline malaria 
AgPf(HRP-2/pLDH) 3 band Rapid Diagnostic Test (RDT) against Giemsa-stained blood smear and evaluate the suitability of this test in assessing 
the therapeutic efficacy of ACT in pediatric malaria patients in the Democratic Republic of the Congo (DRC). Methods: Five hundred and one 
patients with malaria symptoms were screened for P. falciparum in Kinshasa, DRC. Of the 166 patients who tested positive for P. falciparum at 
recruitment (day 0), 103 consented to participate in this study and were followed up and retested for P. falciparum on day 3, day 7, day 14, day 
21 and day 28. Results: Sensitivity and specificity of the test were significantly high on day 0 and so were their positive and negative predictive 
values. Higher proportions of false positive cases were observed on the HRP-2 band irrespective of patient parasite densities during the follow up 
but these were barely seen on the pLDH band. Some patients turned positive during follow up but pLDH readings remained consistent with blood 
smear readings. Conclusion: SD Bioline malaria AgPf(HRP-2/pLDH) RDT demonstrated high performance in DRC. Thus, the test can be employed 
to assess the efficacy of ACT in pediatric malaria patients and prioritize areas that require the deployment of advanced testing like polymerase 
chain reaction (PCR). 
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Introduction 
 
Commercially available rapid diagnostic tests (RDTs) are numerous 
in the market. They all fall into three categories: (i) RDTs that 
detect the Plasmodium falciparum antigen histidine-rich protein 2 
(HRP-2), (ii) RDTs that detect lactate dehydrogenase (pLDH) 
from P. falciparum and (iii) RDTs that detect P. vivax aldolase in 
human whole blood [1]. 
  
Generally, it is known that P. falciparum (Pf) HRP-2 remains in the 
bloodstream for an extended time following a successful clearance 
of the parasite, thus, contributing to false positive results and 
limiting specificity of the test category that targets PfHRP-2 [2]. In 
contrast, pLDH is known to be rapidly cleared from the bloodstream 
and becomes undetectable at about the same time as blood smears 
become negative after a successful anti-malarial therapy [3,4]. 
  
In order to monitor the success of an anti-malarial drug therapy, 
particularly in the presence of fever, pLDH-based tests seem to be 
more useful since they become negative soon after parasites are 
cleared from the blood [3]. Thus, pLDH-based tests better 
discriminate false positive results from treatment failure than HRP-2 
tests. SD Bioline malaria AgPf(HRP-2/pLDH) RDT has been 
reportedly proven to be effective in reducing the rate of false 
positives caused by the persistence of HRP-2 after a successful drug 
therapy and guiding accurate prescription and monitoring efficacy of 
drug therapy in countries like Burkina Faso [4]. However, literature 
on the performance of the RDT in Kinshasa, DRC is scanty. 
  
The objective of this study was to determine the performance of SD 
Bioline malaria AgPf(HRP-2/pLDH) 3 band RDT in symptomatic 
pediatric malaria patients against microscopy of Giemsa-stained 
blood films and to evaluate the effectiveness of SD Bioline malaria 
AgPf(HRP-2/pLDH) in monitoring the efficacy of ACT (artesunate 
amodiaquine) among pediatric patients in Kinshasa, DRC where P. 





Study area, population and procedures 
  
This study was conducted at Tembo Health Center in Kinshasa in 
DRC from October to December 2012. The health facility was 
chosen because of its relatively high number of pediatric patients in 
the 3 months preceding this study. This high number of pediatric 
patients was used as indicative of the availability of sufficient study 
participants. All pediatric patients who presented with symptoms of 
malaria during the study were invited to participate. After obtaining 
consent from patients' parents or guardians, demographic and 
clinical data were collected including previous anti-malarial drug 
intake. Blood samples (finger prick or venous blood) for thick and 
thin blood films and for the SD Bioline malaria AgPf(HRP-2/pLDH) 
RDT were collected from the patients on the day of recruitment (day 
0). Blood slides were stained with Giemsa 3% for 30 minutes. The 
first slide readings were performed at the study site while the 
second readings were conducted at the National Biomedical 
Research Institute in Kinshasa. Those with discrepant results were 
read by a third reader under the supervision of the principal 
investigator, a parasitologist, until when the final agreement was 
reached. Technicians reading blood slides were blinded to the 
results of the SD Bioline malaria AgPf(HRP-2/pLDH) RDT. Likewise, 
those reading the RDT were blinded to the results of the blood 
slides. 
  
SD Bioline malaria AgPf(HRP-2/pLDH) RDT was performed according 
to the manufacturer's instructions and read after 15 minutes by the 
first laboratory technician and then after 30 minutes by the second 
laboratory technician who was blinded to readings from the first 
technician. In case of a discrepancy between the readings, the test 
was repeated. Results were recorded as follows: (i) when the 3 
bands of the test kit were all colored, the test was positive for 
both PfHRP-2 and PfpLDH, (ii) when bands C and T1 were colored, 
the results were positive for Pf HRP-2 and not for PfpLDH, (iii) when 
bands C and T2 were colored, the results were positive for PfpLDH 
and not for PfHRP-2 and (vi) when only band C was colored, the 
results were negative. Parasite density was computed by counting 
the number of parasites/200 white blood cells (WBC) and assuming 
a WBC count of 8,000/µl [6]. 
  
Positive cases of malaria were managed as recommended by the 
DRC National Malaria Control Program and World Health 
Organisation (WHO) [7]. To monitor the persistence of HRP-2/pLDH 
in the blood, respondents were followed for 28 days from day 0. 
Thus, besides day 0, blood samples for thick and thin blood films as 
well as for the SD Bioline malaria Pf (HRP-2/pLHD) RDT were 
collected on day 3, day 7, day 14, day 21 and day 28. The tests 
were performed following the same procedure as described above. 
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Operational case definitions 
  
Sensitivity of the RDT assay is defined herein as its ability to 
correctly detect blood specimens containing malaria antigen. It is 
the percentage of true positive (TP) malaria specimens identified by 
the RDT as positive divided by the number of specimens identified 
by the gold standard assay (Giemsa-stained blood smear) as 
positive (TP) + false negative (FN). 
  
Specificity of the RDT assay is its ability to correctly discriminate 
specimens that do not contain malaria antigen. It is the percentage 
of true negative (TN) specimens identified by the RDT as negative 
divided by the number of specimens identified by the gold standard 
assay as negative (TN) + false positive (FP). 
  
Positive predictive value (PV+) is the probability that when the test 
is reactive, the specimen actually contains malaria antigen. PV+ is 
calculated as TP/(TP + FP). Negative predictive value (PV-) is the 
probability that when a test is negative, a specimen does not have 




Data were entered into MS Excel (Redmond, WA, USA) 
independently by two people. The two datasets were then 
compared and discrepancies were corrected to create the final 
version that was analyzed using IBM SPSS Statistics version 20 
(Chicago, IL, USA). The performance of SD Bioline malaria 
AgPf(HRP-2/pLDH) RDT was assessed by measuring its sensitivity, 
specificity, positive and negative predictive values against blood 
smear microscopy as the gold standard [8]. 
  
The proportion of false positives among the children were estimated 
as a function of PfHRP-2/pLDH antigen present in <1,000 
parasites/µl, 1001 - 5,000 parasites/µl, 5,001 - 50,000 parasites/µl 
and in > 50,000 parasites/µl on day 3, 7, 14, 21 and 28. In other 
words, this represented the percentage of participants who tested 
positive for AgPf(HRP-2/pLDH) RDT while having a negative blood 
smear test for a given parasite density level and day of follow up. 
We compared groups using Fisher’s exact test. The level of 







This study was first approved by the DRC National Biomedical 
Research Institute's Research Committee. Written informed consent 
was sought from parents or guardians of the children who 
participated in this study. The parents or guardians were assured 
that the data would be kept confidential and used only for research 
purposes. Participants who tested positive for malaria were given 
standard malaria management as stipulated by the DRC National 







In total, 501 children were screened for P. falciparum in this study. 
Their mean (standard deviation) age was 26.9 (5.8) months. The 
youngest was 3.4 months old while the oldest was 53.2 months old. 
Two hundred and thirty six (47.1%) participants who were screened 
were females and 265 (52.9%) were males. Three hundred and 
thirty five (66.9%) participants tested negative for malaria while 166 
(33.1%) tested positive for malaria infection. Parents/guardians of 
103 children (out of the 166) gave consent to participate in the 
follow up part of the study, giving a response rate of 62.0%. 
  
SD Bioline malaria AgPf(HRP-2/pLDH) performance 
  
The frequency distribution of the study participants by parasite 
density level is presented in Table 1 whereby the parasitaemia 
bracket 5,001-50,000/μl had the highest percentage of children i.e. 
12.8%. Results of the SD Bioline malaria AgPf(HRP-2/pLDH) RDT 
performance against blood smear microscopy as the gold standard 
are presented in Table 2. SD Bioline malaria AgPf(HRP-2/pLDH) 
RDT exhibited high sensitivity, specificity, positive and negative 
predictive values. Table 3 presents the sensitivity of SD Bioline 
malaria AgPf(HRP-2/pLDH) RDT by level of P. falciparum 
parasitaemia. The sensitivity of SD Bioline malaria AgPf(HRP-
2/pLDH) ranged from 85.1% to 100%. The RDT exhibited its lowest 
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SD Bioline malaria AgPf(HRP-2/pLDH) performance during 
follow up days 
  
One hundred and three patients who were positive for P. 
falciparum on day 0 and their parents or guardians consented to 
participate in this study were followed up till day 28. They were 48 
females and 55 males. Their mean age (standard deviation) was 
31.4 (7.4) months. The youngest was 6 months old and the oldest 
was 50 months. After treatment, on day 3 and day 7, all patients 
tested negative by blood smear microscopy. On day 14, two 
patients became positive by blood smear microscopy and two were 
lost to follow up. On day 21, four more patients became positive 
and six were lost to follow up. On day 28, eleven other patients 
became positive making a total of 17 patients who became positive. 
These cases represented either treatment failure or new infections 
and six more were lost to follow up making a total of 14 children 
lost to follow up. The performance of SD Bioline malaria AgPf(HRP-
2/pLDH) against blood smear microscopy by day of follow up is 
presented inTable 4. 
  
Proportions/percentages of false positives by parasite 
density and by day of follow up 
  
Figure 1 compares the proportions of false positives among 
participants in bands HRP-2 and pLDH on day 3, 7, 14, 21 and 28. 
Band HRP-2 had higher proportions of false positives than pLDH. 
Though the proportion of false positives dropped with days of follow 
up until day 28 it remained significantly higher in band HRP-2. The 
proportions of false positives in band pLDH were significantly (p < 
0.05) lower than those in band HRP-2. In the pLDH band, except for 
patients having parasite densities of 5,001-50,000/µl where a few 
cases of false positives were observed till day 14, no single case of 
false positives was observed among patients with parasite densities 
≤ 1,000/µl on day 3, 7, 14, 21 and 28. There were no false positives 
among children with parasite density ≤ 50,000/µl on 7, 14, 21 and 





The main finding of this study is that the performance of SD Bioline 
malaria AgPf(HRP-2/pLDH) RDT among pediatric patients with 
symptomatic malaria in Kinshasa, DRC was high. The test attributes 
for testing and monitoring the efficacy of ACT treatment among 
pediatric patients in the population studied were reasonably high. 
The sensitivity and specificity of the test were found to be high. The 
corresponding positive and negative predictive values were also high 
indicating the high performance of this test. 
  
Although the sensitivity of the test went a bit down to 85.1% 
among patients with parasite densities ≤ 1,000/μl, this study 
showed sensitivity of about 100% for parasite densities > 1,000/μl. 
Similar results are found in the literature [9,10]. These results 
indicate that when using SD Bioline malaria AgPf(HRP-2/pLDH) RDT 
in this population, the probability of testing positive when one truly 
has malaria is more-or-less 100% which indicates high performance 
of this test in Kinshasa, DRC. 
  
The evaluation of the performance of SD Bioline malaria AgPf(HRP-
2/pLDH) for monitoring the efficacy of ACT treatment showed 
higher proportions of false positives with respect to the HRP-2 band 
irrespective of patient parasites density and day of follow up. This 
means that readings from the test band HRP-2 are not suitable for 
monitoring the efficacy of ACT treatment. The fact that false 
positive cases were barely seen on the pLDH band makes this band 
the most suitable for monitoring the efficacy of ACT treatment. 
Though few cases of false positives were observed among patients 
with parasite densities of 5001- 50,000/µl up to day 14, no single 
case of false positive was observed among patients with other 
parasite densities up to the end of the follow up. The concomitant 
capability of the pLDH band to turn negative when blood smear 
microscopy is negative or positive when blood smear microscopy is 
positive as demonstrated herein is an attribute that makes SD 
Bioline malaria AgPf(HRP-2/pLDH) RDT a suitable test for 
monitoring the efficacy of ACT treatment in this area of highP. 
falciparum transmission. 
  
Considering the high level of P. falciparum transmission in Kinshasa, 
the major limitation of this test is its inability to differentiate 
between true treatment failure and reinfection cases as in total 17 
cases (16.5%) became positive before the end of the study after 
initial successful treatment. Whether these were true cases of 
treatment failure or cases of new infection, only a polymerase chain 
reaction (PCR) procedure can differentiate. PCR is not easily 
accessible in this resource-poor country. Thus, SD Bioline malaria 
AgPf(HRP-2/pLDH) RDT can serve as a guide and a prioritization 
tool for monitoring the efficacy of ACT treatment in communities 
were the study was conducted. Once decreased ACT efficacy is 
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suspected in a community, PCR should then be employed to 





SD Bioline malaria AgPf(HRP-2/pLDH) RDT has been shown to have 
high sensitivity, specificity, positive and negative predictive values 
among pediatric patients with symptomatic malaria in Kinshasa, 
DRC. The RDT's relatively good attributes make it suitable for use as 
a guide in the monitoring of the efficacy of ACT treatment among 
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Table 2: SD Bioline malaria AgPf (HRP-2/pLDH) performance against blood smear microscopy as the gold standard 
  Smear microscopy Performance (%) 
  Results + - Total Sensitivity Specificity PV+ PV- 
RDT Band 
(HRP-2/pLDH) 
+ 158 12 170 
95.2 96.4 92.9 97.6 - 8 323 331 
Total 166 335 501 
RDT = rapid diagnostic test, + = positive, - = negative, PV+ = positive predictive value; PV- = negative predictive value 
 
 
Table 3: Sensitivity of SD Bioline malaria AgPf(HRP-2/pLDH) by level of P. falciparum parasitaemia 
Parasite 
density/ml 
Microscopy HRP-2 pLDH 
+ + Sensitivity + Sensitivity 
0 0 12 NA 12 NA 
≤ 1,000 47 40 85.1 40 85.1 
1,001-5,000 10 10 100 10 100 
5,001-50,000 64 64 100 64 100 
> 50,000 45 44 98.0 44 98.0 
NA = Not applicable 
  
Table 1: Frequency distribution of the study participants by parasite density level 
Parasite density parasites/ml Participants Percentage (%) 
0 335 66.9 
≤ 1,000 47 9.4 
1,001 – 5,000 10 2.0 
5,001 – 50,00 64 12.8 
> 50, 000 45 9.0 
Total 501 100.1 
The total % exceeds 100 because of rounding off 
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Table 4: SD Bioline malaria AgPf(HRP-2/pLDH) performance by day of follow up  
Day 
Microscopy HRP-2 pLDH 
+ - + - Sens (%) Spec (%) + - Sens (%) Spec (%) 
Day 3 0 103 103 0 NA NA 8 95 NA 92.2 
Day 7 0 103 103 0 NA NA 2 101 NA 98.5 
Day 14 2 98 95 5 100 5.1 1 99 50 100 
Day 21 4 90 81 13 100 14.4 0 94 NA 100 
Day 28 11 77 74 14 100 18.2 9 79 81.8 100 




Figure 1: Sensitivity of HRP-2 or pLDH band of the SD Bioline malaria AgPf(HRP-2/pLDH) by 
parasite density in follow up days 
 
